Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-07-25
|
PEGPH20 and pembrolizumab |
non-small cell lung cancer (NSCLC), gastric cancer |
1b |
Halozyme Therapeutics (USA - CA) |
Cancer - Oncology |
2016-07-25
|
afatinib |
metastatic and recurrent head and neck cancer |
3 |
Boehringer Ingelheim (Germany) |
Cancer - Oncology |
2016-07-22
|
human Retinal Progenitor Cell (hRPC) therapy |
retinitis pigmentosa |
preclinical |
Reneuron (UK) |
Ophtalmological diseases |
2016-07-21
|
CA4P (fosbretabulin tromethamine) and pazopanib |
ovarian cancer |
1b-2 |
Mateon Therapeutics (USA - CA), Novartis (Switzerland) |
Cancer - Oncology |
2016-07-21
|
crenolanib |
advanced or metastatic gastrointestinal stromal tumors (GIST) with D842V mutated PDGFRA gene |
3 |
Arog Pharmaceuticals (USA -TX) |
Cancer - Oncology |
2016-07-21
|
Odefsey®(emtricitabine 200mg/rilpivirine 25mg/tenofovir alafenamide 25mg) |
HIV-1 infection |
3b |
Gilead Sciences (USA - CA) |
Infectious diseases |
2016-07-21
|
neratinib - PB272 |
extended adjuvant treatment of HER2-positive early stage breast cancer |
3 |
Puma Biotechnology (USA - CA) |
Cancer - Oncology |
2016-07-21
|
ABP 980 (biosimilar version of trastuzumab - Herceptin®) |
breast cancer |
3 |
Amgen (USA - CA) Allergan (Ireland) |
Cancer - Oncology |
2016-07-19
|
ZGN-440 (beloranib) |
Prader-Willi syndrome |
3 |
Zafgen (USA - MA) |
Rare diseases - Genetic diseases - Metabolic diseases |
2016-07-19
|
ZGN-440 (beloranib) |
severe obesity complicated by type 2 diabetes |
2b |
Zafgen (USA - MA) |
Metabolic diseases |
2016-07-18
|
megaTAL genome editing platform |
|
|
Bluebird bio (USA - MA) |
|
2016-07-18
|
AB-PA01 - AmpliPhage-001 (Pseudomonas aeruginosa bacteriophages) |
Pseudomonas aeruginosa infections |
preclinical |
AmpliPhi BioSciences (USA - VA) |
Infectious diseases - Rare diseases |
2016-07-18
|
Adcetris® (brentuximab vedotin) |
relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) |
2 |
Seattle Genetics (USA - WA) Takeda Pharmaceutical (Japan) |
Cancer - Oncology |
2016-07-15
|
ALD403 |
chronic migraine |
2b |
Alder Biopharmaceuticals (USA - WA) |
CNS diseases - Neurological diseases |
2016-07-14
|
RNActive® technology |
|
|
Curevac (Germany) |
Infectious diseases |
2016-07-14
|
|
hypertrophic cardiomyopathy |
registry study |
Myokardia (USA - CA) |
Cardiovascular diseases |
2016-07-14
|
AGS-004 and vorinostat |
HIV infection |
2 |
Argos Therapeutics (USA - NC) |
Infectious diseases |
2016-07-14
|
recombinant human beta-glucuronidase (rhGUS, UX003) |
mucopolysaccharidosis 7 (MPS 7, Sly syndrome) |
3 |
Ultragenyx Pharmaceutical (USA - CA) |
Rare diseases - Genetic diseases - Metabolic diseases |
2016-07-13
|
BI 836845 and abemaciclib (LY2835219) |
metastatic breast cancer |
2 |
Boehringer Ingelheim (Germany) Eli Lilly (USA - IN) |
Cancer - Oncology |
2016-07-12
|
IMP321 |
solid tumors |
1 |
Prima Biomed (Australia) Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH (Germany) |
Cancer - Oncology |